Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Article, Review English OPEN
Rawla,Prashanth; Sunkara,Tagore; Raj,Jeffrey Pradeep;
(2018)
  • Publisher: Dove Press
  • Journal: Journal of Inflammation Research,volume 11,pages215-226 (issn: 1178-7031, eissn: 1178-7031)
  • Publisher copyright policies & self-archiving
  • Related identifiers: pmc: PMC5961645, doi: 10.2147/JIR.S165330
  • Subject: RB1-214 | Cimzia | Humira | Pathology | Infliximab | Simponi® | Entyvio | Crohn’s disease | Cimzia® | Adalimumab | Golimumab | Ustekinumab | Tysabri® | Stelara® | Stelara. | Review | Journal of Inflammation Research | Biosimilars | Ulcerative Colitis | Integrin | Interleukin | Natalizumab | Simponi | Vedolizumab | Biologics | Remicade® | Certolizumab | Tysabri | Inflammatory Bowel Disease | Tumor Necrosis Factor | Humira® | Crohn's Disease | Remicade
    mesheuropmc: digestive system diseases

Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Si... View more
Share - Bookmark